TY - JOUR
T1 - A prospective trial of midwest breast cancer patients
T2 - A p53 gene mutation is the most important predictor of adverse outcome
AU - Blaszyk, Hagen
AU - Hartmann, Arndt
AU - Cunningham, Julie M.
AU - Schaid, Daniel
AU - Wold, Lester E.
AU - Kovach, John S.
AU - Sommer, Steve S.
PY - 2000/1/20
Y1 - 2000/1/20
N2 - Several retrospective studies have suggested p53 gene mutation as an adverse prognostic indicator in breast cancer patients, based on a selective growth advantage of p53 mutant cancer cells and their presumed resistance to current adjuvant therapy regimens. A cohort of 90 Caucasian midwestern breast cancer patients was analyzed prospectively (60 months of follow-up) with a rigorous mutation detection methodology. The presence of a p53 gene mutation was the single most adverse prognostic indicator for recurrence (p = 0.0032) and death (p = 0.0001), and was associated with poor response to both adjuvant (p = 0.0001) and palliative (p = 0.006) therapy. Analysis of the p53 gene with appropriate mutation detection methodology markedly improves the prediction of early recurrence, treatment failure, and death in breast cancer patients. (C) 2000 Wiley-Liss, Inc.
AB - Several retrospective studies have suggested p53 gene mutation as an adverse prognostic indicator in breast cancer patients, based on a selective growth advantage of p53 mutant cancer cells and their presumed resistance to current adjuvant therapy regimens. A cohort of 90 Caucasian midwestern breast cancer patients was analyzed prospectively (60 months of follow-up) with a rigorous mutation detection methodology. The presence of a p53 gene mutation was the single most adverse prognostic indicator for recurrence (p = 0.0032) and death (p = 0.0001), and was associated with poor response to both adjuvant (p = 0.0001) and palliative (p = 0.006) therapy. Analysis of the p53 gene with appropriate mutation detection methodology markedly improves the prediction of early recurrence, treatment failure, and death in breast cancer patients. (C) 2000 Wiley-Liss, Inc.
UR - http://www.scopus.com/inward/record.url?scp=0034688185&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0034688185&partnerID=8YFLogxK
U2 - 10.1002/(SICI)1097-0215(20000120)89:1<32::AID-IJC6>3.0.CO;2-G
DO - 10.1002/(SICI)1097-0215(20000120)89:1<32::AID-IJC6>3.0.CO;2-G
M3 - Article
C2 - 10719728
AN - SCOPUS:0034688185
SN - 0020-7136
VL - 89
SP - 32
EP - 38
JO - International Journal of Cancer
JF - International Journal of Cancer
IS - 1
ER -